Binzhou Medical University, Yantai, Shandong 264003, PR China; Department of Medical Oncology, Affiliated Hospital of Binzhou Medical College, Binzhou 256600, Shandong, PR China.
Binzhou Medical University, Yantai, Shandong 264003, PR China.
Eur J Pharmacol. 2015 May 5;754:105-14. doi: 10.1016/j.ejphar.2015.02.015. Epub 2015 Feb 24.
Hydroxysafflor yellow A (HSYA), a flavonoid derived and isolated from traditional Chinese medicine Carthamus tinctorius L., possesses anti-tumor activity. However, its effects on hepatocellular carcinoma (HCC) have not been investigated. The proliferation and metastasis of HCC are dependent on angiogenesis, which also strongly links with several signal transduction pathways associated with cell proliferation and apoptosis. This study aimed to explore the effect of HSYA on vasculogenesis and to determine its molecular mechanism by investigating the expression of ERK/MAPK (p-c-Raf, c-Raf, p-ERK1/2, ERK1/2) and NF-κB (p65, IκB and p-IκB) signaling pathway in H22 tumor-bearing mice. The results showed that HSYA could considerably suppress tumor growth by inhibiting secretion of angiogenesis factors (vascular endothelial growth factor A, basic fibroblast growth factor) and vascular endothelial growth factor receptor1. At the moleculcould block ERK1/2 phosphorylation and then restrain the activation of NF-κB and its nuclear translocation by down-regulating the expression of p65 in the nucleus, up-regulating p65 level in the cytoplasm, inhibiting IκB phosphorylation and cytoplasmic degradation of IκB-α. Finally, we demonstrate that HSYA could suppress mRNA expression levels of cell proliferation-related genes (cyclinD1, c-myc, c-Fos) compared with negative control group. And best of all, HSYA could improve spleen/thymus indexes, which was evaluated as the marker of protective effect on the immune system. Our findings support HSYA as a promising candidate for the prevention and treatment of HCC.
羟基红花黄色素 A(HSYA)是从传统中药红花中提取和分离得到的一种类黄酮,具有抗肿瘤活性。然而,其对肝癌(HCC)的作用尚未得到研究。肝癌的增殖和转移依赖于血管生成,而血管生成与与细胞增殖和凋亡相关的几个信号转导途径密切相关。本研究旨在通过研究 ERK/MAPK(p-c-Raf、c-Raf、p-ERK1/2、ERK1/2)和 NF-κB(p65、IκB 和 p-IκB)信号通路在 H22 荷瘤小鼠中的表达,探讨 HSYA 对血管生成的影响及其分子机制。结果表明,HSYA 可通过抑制血管生成因子(血管内皮生长因子 A、碱性成纤维细胞生长因子)和血管内皮生长因子受体 1 的分泌,显著抑制肿瘤生长。在分子水平上,HSYA 可以通过下调核内 p65 的表达、上调胞质内 p65 的水平、抑制 IκB 的磷酸化和 IκB-α的胞质降解,从而阻断 ERK1/2 的磷酸化,进而抑制 NF-κB 的激活及其核转位。最后,我们证明 HSYA 可与阴性对照组相比,抑制与细胞增殖相关的基因(cyclinD1、c-myc、c-Fos)的 mRNA 表达水平。更重要的是,HSYA 可以改善脾脏/胸腺指数,这被评估为对免疫系统的保护作用的标志物。我们的研究结果支持 HSYA 作为预防和治疗 HCC 的有前途的候选药物。